Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
Nuklearmedizin - NuclearMedicine · 01.04.2026 · 65 (02) · 107
DOI: 10.1055/s-0046-1818191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2026. Verfasst von S Tagawa und 19 weiteren Autor:innen.
Abstract (Originalsprache)
Ziel/Aim: ADT+androgen receptor pathway inhibitor (ARPI) is a standard of care for mHSPC but outcomes remain suboptimal. PSMAddition (NCT04720157) evaluates [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) combined with ADT+ARPI in PSMA+mHSPC. Methodik/Methods: Eligible adults had treatment-naïve/minimally treated (≤45 days) mHSPC and≥1 PSMA+metastatic lesion on [ 68 Ga]Ga-PSMA-11 PET/CT. Randomization was 1:1 to open-label 177 Lu-PSMA-617 (7.4 GBq q6w, 6 cycles)+ADT+ARPI ( 177 Lu-PSMA-617 arm) or ADT+ARPI (control arm), stratified by disease volume (high/low), age (≥/
Zitieren
APA
Tagawa, S., Sartor, O., Piulats, J. M., Saad, F., Fizazi, K., Reid, A. H., Beltran, H., Kramer, G., Mahammedi, H., Eiber, M., Gupta, S., Gauna, D. E. C., Hauke, R., Kim, H., Kwak, C., Pang, S., Bouillaud, E., Zhang, A., Sakharova, O., & Morris, M. J. (2026). Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Nuklearmedizin - NuclearMedicine, 65(02), 107. https://doi.org/10.1055/s-0046-1818191
Vancouver
Tagawa S, Sartor O, Piulats JM, Saad F, Fizazi K, Reid AH, et al. Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Nuklearmedizin - NuclearMedicine. 2026;65(02):107. doi:10.1055/s-0046-1818191
BibTeX
@article{Tagawa2026,
author = {Tagawa, S and Sartor, O and Piulats, J M and Saad, F and Fizazi, K and Reid, A H and Beltran, H and Kramer, G and Mahammedi, H and Eiber, M and Gupta, S and Gauna, D E Castellano and Hauke, R and Kim, H and Kwak, C and Pang, S-T and Bouillaud, E and Zhang, A and Sakharova, O and Morris, M J},
title = {Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2026},
volume = {65},
number = {02},
pages = {107},
doi = {10.1055/s-0046-1818191}
}
EUVIMED